The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy-Reference-Cited by-同舟云学术

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

Published:2007-01 Issue:10 Volume:48 Page:1931-1939
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Tam Constantine S.,O'Brien Susan,Lerner Susan,Khouri I.,Ferrajoli A.,Faderl S.,Browning M.,Tsimberidou Apostolia M.,Kantarjian Hagop,Wierda William G.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10428190701573257

Reference34 articles.

1. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia

2. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

3. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

4. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BTK inhibitors in CLL: second-generation drugs and beyond;Blood Advances;2024-05-14

2. Upfront therapy: the case for continuous treatment;Hematology;2021-12-10

3. Clinical significance of TP53 aberrations and IGHV mutational status in chronic lymphocytic leukemia;Medicinski podmladak;2020

4. Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin – Prelimary results;Annals of Agricultural and Environmental Medicine;2018-03-14

5. BCL2 Inhibitors: Insights into Resistance;Resistance to Targeted Anti-Cancer Therapeutics;2018